Evidence map›Paper›PMID 39465618›Full record

ArticleJournal of pediatric gastroenterology and nutrition2024

Impact of acid blocker therapy on growth, gut microbiome, and lung disease in young children with cystic fibrosis.

Cathy Liu, Taiya R Bach, Philip M Farrell, Derek Pavelec, Nicholas J Antos, Michael J Rock, Fadi Asfour, Michelle Howenstine, Jonathan M Gaffin, HuiChuan J Lai

Registry-linked trialAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pediatric gastroenterology and nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07036627 (Evaluation of the Intestinal Microbiota in Pediatric Patients Treated With Proton Pump Inhibitors), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07036627 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Evaluation of the Intestinal Microbiota in Pediatric Patients Treated With Proton Pump Inhibitors: A Prospective Longitudinal Study

TypeobservationalSponsorUniversity of BariRan2025 to 2027Enrolled100ConditionsProton Pump Inhibitors, Human Gastrointestinal Tract, Gastroesophageal Reflux DiseaseArmsstudy of microbiota
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Cystic Fibrosis Year in Review 2024.Pediatric pulmonology · 2025
    Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Cathy LiuDepartment of Pediatrics, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
Taiya R BachDepartment of Nutritional Sciences, College of Agriculture and Life Sciences, University of Wisconsin, Madison, Wisconsin, USA.
Philip M FarrellDepartment of Pediatrics, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
Derek PavelecBioinformatics Resource Center, UW Biotechnology Center, University of Wisconsin-Madison, Wisconsin, USA.
Nicholas J AntosDepartment of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Michael J RockDepartment of Pediatrics, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
Fadi AsfourDepartment of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
Michelle HowenstineDepartment of Pediatrics, Indiana University, Indianapolis, Indiana, USA.
Jonathan M GaffinDepartment of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA.
HuiChuan J LaiDepartment of Pediatrics, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.

Funding

Newborn Screening, Malnutrition and Lung Disease in Children with Cystic FibrosisR01DK072126 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI LAI, HUICHUAN J · 2006 to 2015
$4.3M
Early Childhood Diet, Growth, Gut Microbiome And Lung Health in Cystic FibrosisR01DK109692 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI LAI, HUICHUAN J · 2016 to 2021
$3.8M
Early Childhood Diet, Growth, Gut Microbiome and Lung Health in Cystic FibrosisR56DK109692 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI LAI, HUICHUAN J · 2015 to 2015
$150k
CF Foundation LAI14A0CF Foundation LAI15A0CF Foundation LAI17A0NIDDK NIH HHS R01 DK072126NIDDK NIH HHS R01 DK109692NIDDK NIH HHS R56 DK109692NIH HHS R01 DK072126NIH HHS R01 DK109692NIH HHS R56 DK109692University of Wisconsin School of Medicine and Public Health
6 · The paper itself

Abstract

objectiveAcid blocker therapy (ABT) has become common in cystic fibrosis (CF), despite insufficient evidence for benefits and studies showing potentially negative effects. We examined associations between ABT usage and growth, gut microbiome (GM), and early-onset lung disease in young children with CF.

methodsOne hundred and forty-five infants with CF born during 2012-2017, diagnosed through newborn screening by age 3 months and followed to 36 months of age at six CF centers were evaluated. Longitudinal data on growth, pancreatic functional status, pulmonary symptoms, and acid blocker medications were prospectively collected. Early-onset lung disease severity was evaluated by a clinical scoring system. GM composition was assessed by 16S rRNA methodology.

resultsABT use before age 3 years was frequent, with 81 (56%) of patients on H2 receptor antagonist (H2RA) or proton pump inhibitor (PPI), and higher among pancreatic insufficient (60%) versus pancreatic sufficient (26%) children. H2RA was commonly prescribed in infancy before transitioning to PPI. Growth improvements were not significantly greater, while GM α-diversity at 3 years of age was significantly lower and early-onset lung disease more severe, in persistent ABT users compared to nonusers of ABT.

conclusionIn our cohort of young children with CF, early and persistent ABT use was not associated with significant growth benefits and instead showed associations with reduced GM diversity and negative effects on early-onset lung disease. Consequentially, there is a critical need for systematic evaluation and comprehensive risk-benefit analysis of ABT to ensure proper guidelines for children with CF.

Indexed as

Cystic FibrosisGastrointestinal MicrobiomeHistamine H2 AntagonistsProton Pump InhibitorsChild, PreschoolFemaleHumansInfantInfant, NewbornLung DiseasesMaleProspective StudiesHistamine H2 AntagonistsProton Pump Inhibitorsgastroesophgeal refluxmalnutritionpancreatic insufficiencyproton pump inhibitorspulmonary exacerbation

Identifiers

PMID39465618
PMCPMC11615133

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.